Press Releases

Feb 8, 2012
Discovery Labs Signs Manufacturing Agreement For AFECTAIR®

Feb 2, 2012
Discovery Labs Cleared to Market AFECTAIR in U.S. Click here to listen

Dec 6, 2011
New Study Shows AFECTAIR® Significantly Improved Delivery of Nitric Oxide Under Simulated Neonatal Ventilatory Conditions

Nov 11, 2011
Discovery Labs to Present at the Lazard Capital Markets Healthcare Conference

Nov 10, 2011
Discovery Labs Reports Third Quarter Financial Results and Progress on Lead Programs Click here to listen

Nov 8, 2011
Discovery Labs Releases New AFECTAIRTM Performance Data Presented at the American Association for Respiratory Care Annual Meeting

Nov 3, 2011
Discovery Labs’ KL4 Surfactant Granted Orphan Drug Designation in Europe for the Treatment of Cystic Fibrosis

Nov 2, 2011
Discovery Labs AFECTAIRTM Technology to Be Presented at the American Association for Respiratory Care Annual Meeting

Oct 28, 2011
Discovery Labs to Report Third Quarter 2011 Results and Hold Conference Call on Thursday, November 10, 2011

Oct 19, 2011
Discovery Labs Aerosolized KL4 Surfactant Program Data Presented at the European Society for Paediatric Research Annual Meeting

Oct 18, 2011
New Study Shows Neonatologists and Parents of NICU Infants Share Concern Regarding Newborn Exposure to Animal-Derived Medications

Sept 29, 2011
Discovery Labs Proprietary Aerosol Drug Delivery Technology Showcased at the 2011 AdvaMed Annual Meeting

Sept 28, 2011
Discovery Labs Notified of PDUFA Date for SURFAXIN® Click here to listen

Sept 6, 2011
Discovery Labs Submits SURFAXIN® Complete Response to FDA

Aug 3, 2011
Discovery Labs Reports Second Quarter Financial Results and Provides an Update on Lead Pipeline Programs Click here to listen

July 29, 2011
Discovery Labs Aerosolization Program Yields Potential New Product Offering: AFECTAIR TM Click here to listen

July 22, 2011
Discovery Labs Announces Date of 2011 Annual Stockholder Meeting

July 22, 2011
Discovery Labs to Report Second Quarter 2011 Results and Hold Conference Call on Wednesday August 3, 2011

June 22, 2011
Discovery Labs’ Proprietary Aerosol Drug Delivery Technology Showcased at the International Society for Aerosols in Medicine Annual Meeting

June 1, 2011
Analysis of Surfaxin Data Presented in First Peer-Reviewed Manuscript Describing the Consequences of Reintubation in Preterm Neonates

May 11, 2011
Discovery Labs Reports First Quarter Financial Results and Provides an Update on Key Pipeline Programs Click here to listen

May 4, 2011
Discovery Labs’ Aerosolized KL4 Surfactant Program Data Presented at the Pediatric Academic Societies Annual Meeting

May 3, 2011
Discovery Labs’ Aerosolized KL4 Surfactant Significantly Improves Lung Function and Survival in Established Model of Acute Lung Injury

April 28, 2011
Discovery Labs Announces First Quarter 2011 Conference Call Click here to listen

April 20, 2011
Discovery Labs’ KL4 Surfactant Aerosolization Program Data to be Presented at the Pediatric Academic Societies Annual Meeting

March 22, 2011
Discovery Labs Reports Fourth Quarter Financial Results and Provides an Update on Key Pipeline Programs Click here to listen

March 10, 2011
Discovery Labs Announces Quarterly Business Update Conference Call

February 23, 2011
Discovery Labs Announces Completion of $23.5 Million Public Offering

February 16, 2011
Discovery Labs Prices $23.5 Million Public Offering of Common Stock and Warrants

February 15, 2011
Discovery Labs Announces Proposed Public Offering of Common Stock and Warrants

February 1, 2011
Discovery Labs Provides Expanded Update Regarding its Program for Surfaxin® U.S. Marketing Authorization Click here to listen to replay

January 27, 2011
Discovery Labs to Host a Conference Call to Provide an Overview of its Program for Surfaxin® U.S. Marketing Authorization

January 19, 2011
Discovery Labs Receives U.S. Patent Covering Pulmonary Surfactant and Protease Inhibitor Combination Products for Pulmonary Conditions

January 12, 2011
Discovery Labs Announces that Nasdaq Hearing Panel has Granted Request for Continued Listing on The NASDAQ Capital Market®

January 10, 2011
Discovery Labs Provides Update Regarding its Program for Surfaxin® U.S. Marketing Authorization

December 27, 2010
Discovery Labs Announces Reverse Stock Split

December 16, 2010
NIH Awards Discovery Labs Fast Track SBIR Grant to Support Development of Aerosolized KL4 Surfactant

December 7, 2010
Leading Proxy Advisory Firms Recommend that Discovery Labs’ Stockholders Vote “FOR” Important Proposals at Annual Meeting of Stockholders

December 7, 2010
Discovery Labs Aerosurf® Improves Lung Function and Reduces Inflammation in a Dose-dependent Fashion in Established Non-Clinical Model of Preterm Respiratory Distress Syndrome

December 3, 2010
Discovery Labs Receives Nasdaq Delisting Notification Related to Minimum Bid Price and Plans to File Request for Hearing

November 15, 2010
Discovery Labs to Present at the Lazard Capital Markets Healthcare Conference

November 9, 2010
Discovery Labs Provides a Third Quarter 2010 Business and Financial Update

November 2, 2010
Discovery Labs Announces Pipeline and Business Update Conference Call

November 1, 2010
Discovery Labs’ KL4 Surfactant Granted Orphan Drug Designation for the Treatment of Cystic Fibrosis

October 22, 2010
Discovery Labs Announces Presentation & Key Results of Phase 2a Study of Aerosolized KL4 Surfactant in Cystic Fibrosis at the North American Cystic Fibrosis Conference

October 15, 2010
Discovery Labs Announces Completion of Phase 2a Study of Aerosolized KL4 Surfactant in Cystic Fibrosis

October 15, 2010
Discovery Labs Appoints W. Thomas Amick as Chief Executive Officer

October 13, 2010
PharmaBio Expands Investment in Discovery Labs to Advance Surfaxin LSTM and Aerosurf® Programs

September 22, 2010
Study Comparing Discovery Labs’ Surfaxin® vs. Curosurf® Published in Pediatric Research

September 21, 2010
Discovery Labs Appoints Thomas C. Hoy as Vice President of Manufacturing Operations

September 15, 2010
Bruce A. Peacock Joins Discovery Labs’ Board of Directors

August 24, 2010
Discovery Labs Realigns Executive Management

August 11, 2010
Discovery Labs to Present at the Global Hunter Securities Healthcare Conference
Click here to listen to the presentation

August 4, 2010
Discovery Labs Provides Business Update and Reports Second Quarter 2010 Financial Results

July 28, 2010
Discovery Labs Announces Conference Call

June 17, 2010
Discovery Labs Prices $10.0 Million Public Offering of Common Stock and Warrants

June 16, 2010
Discovery Labs Announces Proposed Public Offering of Common Stock and Warrants

June 14, 2010
Discovery Labs Secures $35 Million Committed Equity Financing Facility

June 9, 2010
Discovery Labs Reports Preliminary Results from Phase 2 Clinical Trial of Surfaxin in Pediatric Acute Respiratory Failure

June 8, 2010
Discovery Labs Receives FDA Guidance Regarding Preclinical Program to Gain SURFAXIN® Approval

June 2, 2010
Discovery Labs Announces Listing Transfer to NASDAQ Capital Market

May 19, 2010
Discovery Labs Achieves Key Milestone Towards Potential Surfaxin® Approval

May 17, 2010
Discovery Labs’ KL4 Surfactant Demonstrates Potential Protective Role for Lung Transplantation in Established Preclinical Model

May 14, 2010
Discovery Labs’ Phase 2a Aerosurf® Study Published in Journal of Aerosol Medicine and Pulmonary Drug Delivery

May 5, 2010
Surfaxin LSTM Improves Pulmonary Function and Reduces Lung Inflammation in Established Model of Respiratory Distress Syndrome

April 28, 2010
Discovery Labs’ KL4 Surfactant Data to be Presented at Pediatric Academic Societies Annual Meeting and American Thoracic Society International Conference

April 27, 2010
Discovery Labs Provides Updates on Surfaxin®, Other Key Programs and First Quarter 2010 Financial Results

March 10, 2010
Discovery Labs Reports Fourth Quarter 2009 Financial Results and Provides Business Update

February 23, 2010
Discovery Labs Announces Completion of $16.5 Million Public Offering

February 18, 2010
Discovery Labs Prices $16.5 Million Public Offering of Common Stock and Warrants

February 17, 2010
Discovery Labs Announces Proposed Public Offering of Common Stock and Warrants

February 16, 2010
Discovery Labs Receives FDA Guidance Regarding Pathway to Potential SURFAXIN® Approval

January 19, 2010
POPG, a Key Component of Discovery Labs KL4 Surfactant, Identified as a Novel Anti-Viral Therapeutic Approach

2009 Press Releases

2008 Press Releases

2007 Press Releases

2006 Press Releases

2005 Press Releases

The press releases and information stored here shall not constitute an offer to sell or a solicitation of an offer to buy any securities of the Company. To the extent that statements in the press releases and information stored here are not strictly historical, including statements as to the Company's business strategy, outlook, objectives, plans, intentions, goals, future financial conditions, future collaboration agreements, the success of the Company's product development, or otherwise as to future events, such statements are forward-looking, and are made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. The forward-looking statements contained in these releases are subject to certain risks and uncertainties that could cause actual results to differ materially from the statements made. Among the factors which could affect the Company's actual results and could cause  results to differ from those contained in the forward-looking statements contained herein are the risk that financial conditions may change, the risk that the Company will not be able to raise additional capital or enter into additional collaboration agreements, risks relating to the progress of the Company's research and development and the development of competing therapies and/or technologies by other companies.  Those associated risks and others are further described in the Company's periodic filings with the Securities and Exchange Commission, including the most recent reports on Forms 10-KSB, 8-K, 10-QSB and 10-Q, and amendments thereto.